Avastin (bevacizumab) indicated in mCRC, NSCLC, mBC, mRCC and advanced ovarian cancer in combination with chemotherapy. Information from Roche for healthcare professionals.

Educational webcast

Educational webcast

Professor Colombo discusses the eligibility of patients for treatment with front‐line bevacizumab and the recommended management of hypertension

Expert perspective

VEGF: A Target in Ovarian Cancer

Prof. Stan Kye
UK
Avastin MoA

Interactive modular MoA slide set with a detailed voiceover
Patient case

A patient with hormone receptor-positive breast cancer

Dr Sunil Verma
Canada

Patient case

A patient with centrally located adenocarcinoma of the lung

Dr Martin Reck
Germany
Educational webcast

Incorporation of bevacizumab in the primary treatment of Ovarian cancer

Prof. Robert Burger
USA
Expert perspective

Safety of Avastin in CRC

Prof. Eric Van Cutsem
Belguim

<>

Resources
Webcasts
Patient cases

Expert perspectives
Tolerability of Avastin (Prof. Hans Joachim-Schmoll)
Expert perspective
Importance of prolonging life (Prof. Manuela Schmidinger)
Expert perspectives in ovarian cancer
Avastin in OC is exciting (Prof. Eric Pujade Lauraine)

Bevacizumab plus IFN in mRCC
Latest clinical trial data on the efficacy of first-line Avastin plus IFN in mRCC (Dr Camillo Porta)
From tumour biology to biomarkers
An insight into the evolving role of biomarkers for anti-angiogenesis therapy in oncology (Dr Donald McDonald)
Clinical endpoints in oncology
A discussion of clinical trial endpoints used in oncology trials and how these translate into patient benefit (Dr Artur Katz)

CRC patient case
A patient with colon adenocarcinoma with borderline resectable liver-only metastases (Dr Mark Kozloff)
NSCLC patient case
A patient with adenocarcinoma of the lung and pre-existing hypertension (Dr Monika Serke)
mBC patient case
A patient with triple-negative breast cancer (Dr Thierry Petit)

Upcoming conferences

ASCO
,
Chicago, USA

31 May 2013 - 04 June 2013
WCGC
,
Barcelona, Spain

3-6 July 2013
Biomarker World Congress
,
Philadelphia, USA

15-17 July 2013

More upcoming conferences

You are now leaving the www.avastin.net website. Links to all external sites are provided as a resource to our visitors. Hoffmann-La Roche Inc. ("Roche") accepts no responsibility for the content of these sites. Roche does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Roche, except where indicated. We recommend that you consult with your physician or other healthcare provider to obtain more information about any Roche prescription medication.